Statement of Changes in Beneficial Ownership (4)
May 17 2023 - 4:31PM
Edgar (US Regulatory)
FORM 4
☐
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Fitzgerald Joseph Michael |
2. Issuer Name and Ticker or Trading Symbol
BOSTON SCIENTIFIC CORP
[
BSX
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) EVP & Group Pres, Cardiology |
(Last)
(First)
(Middle)
300 BOSTON SCIENTIFIC WAY |
3. Date of Earliest Transaction
(MM/DD/YYYY)
5/16/2023 |
(Street)
MARLBOROUGH, MA 01752-1234 |
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
(City)
(State)
(Zip)
|
Rule 10b5-1(c) Transaction Indication
☐
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to
satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 5/16/2023 | | M(1) | | 56921.0000 | A | $13.0800 | 277198.0000 | D | |
Common Stock | 5/16/2023 | | S(1) | | 63339.0000 | D | $53.5982 (2) | 213859.0000 | D | |
Common Stock | | | | | | | | 68044.0000 (3) | I | By 401(k) |
Common Stock | | | | | | | | 4344.0000 (4) | I | By Child |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Stock Option (Right to Buy) | $13.0800 | 5/16/2023 | | M (1) | | | 56921.0000 | (5) | 2/24/2024 | Common Stock | 56921.0000 | $0.0000 | 0.0000 | D | |
Explanation of Responses: |
(1) | The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 15, 2023, intended to comply with the prior version of Rule 10b5-1(c). |
(2) | Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $53.37 to $53.80, inclusive. The reporting person undertakes to provide upon request by the U.S.Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. |
(3) | Balance reflects the most current data available with regard to share holdings in the Company's 401(k) Retirement Savings Plan. |
(4) | The reporting person disclaims beneficial ownership of the shares held by his child, and this report should not be deemed an admission that the reporting person is the beneficial owner of his child's shares for purposes of Section 16 or for any other purpose. |
(5) | Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Fitzgerald Joseph Michael 300 BOSTON SCIENTIFIC WAY MARLBOROUGH, MA 01752-1234 |
|
| EVP & Group Pres, Cardiology |
|
Signatures
|
/s/ Susan Thompson, Attorney-in-Fact | | 5/17/2023 |
**Signature of Reporting Person | Date |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. |
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
Boston Scientific (NYSE:BSX-A)
Historical Stock Chart
From Jun 2024 to Jul 2024
Boston Scientific (NYSE:BSX-A)
Historical Stock Chart
From Jul 2023 to Jul 2024